Abstract：ObjectiveTo study the serum levels of acylated ghrelin（AG）and nesfatin-1 in adult patients with primary epilepsy in the pretreatment period and six months after carbamazepine (CBZ) or valproic acid(VPA) therapy.MethodsFifty adult patients with primary epilepsy ［30 with secondary generalized epilepsy (SGE),20 with primary generalized epilepsy (PGE)］ and 20 control patients were included in this study.Serum levels of AG and nesfatin-1 were measured in these groups in the pretreatment period and six months after treatment.ResultsSerum level of AG in control group was (42.49±8.24)ng/L,pretherapy serum level of AG in SGE （32.67±5.64）ng/L was lower than that in control group （t=2.08，P<0.05）.Post-CBZ therapy serum level of AG （54.31±7.91）ng/L was higher than that in pretherapy （t=2.80，P<0.05）.Pretherapy serum level of AG in PGE （31.56±6.32）ng/L was lower than that in control group（t=2.09，P<0.05）,post-VPA therapy serum level of AG （51.37±7.56）ng/L was higher than that in pretherapy（t=3.22，P<0.05）.Serum level of nesfatin-1 in control group was (0.66±0.02)μg/L.Pretherapy serum level of nesfatin-1 in SGE ［（6.57±0.93）μg/L］ was higher than that in control group（t=2.18，P<0.05）,post-CBZ therapy serum level of nesfatin-1 ［（2.74±0.56）μg/L］ was also higher than that in control group（t=2.05，P<0.05）.Pretherapy serum level of nesfatin-1 in PGE （9.04±1.32）μg/L was higher than that in control group （t=3.83，P<0.05）,post-VPA therapy serum level of nesfatin-1（3.28±0.43）μg/L was also higher than that in control group （t=2.24，P<0.05）.ConclusionAG may have protective effects on neurons and have antiepilepsy effects,nesfatin-1 may serve as biomarker for the diagnosis of primary epilepsy.
